BeOne Medicines AG Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹32.3K Cr
- BeOne Medicines projects 2026 revenue between $6.3 billion and $6.5 billion, raising previous guidance by $100 million. - Strong momentum and growth expected in all markets, supported by continued global expansion. - Modest contributions anticipated from launches of zanidatamab and Sonro during 2026. - U.S. - BeOne Medicines is a growth company focused on sustainable growth with continuous operating leverage (Page 13).
From BeOne Medicines AG's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹290.58
Market Cap
₹32.3K Cr
P/E Ratio
68.6
Revenue Rank
Margin Rank
How does BeOne Medicines AG rank in Biotechnology?
Compare BeOne Medicines AG against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →BeOne Medicines projects 2026 revenue between $6.3 billion and $6.5 billion, raising previous guidance by $100 million.
- →Strong momentum and growth expected in all markets, supported by continued global expansion.
- →Modest contributions anticipated from launches of zanidatamab and Sonro during 2026.
- →U.S. market shows strong demand growth with relatively stable net pricing.
- →Europe demonstrates robust growth (64% increase), with opportunities to further increase BRUKINSA brand share.
- →Rest of World markets grew 104%, driven by expansions and launches in key regions such as Japan and Brazil.
- →BRUKINSA sales were $1.1 billion in Q1, growing 38% year-over-year, with strong performance across all indications and geographies.
- →Pipeline advances, especially in hematology and solid tumors, forecast sustained revenue growth driven by new approvals and product launches.
📈 Profitability & Margins
Rank 3- →BeOne Medicines is a growth company focused on sustainable growth with continuous operating leverage (Page 13).
- →They have achieved meaningful positive operating income and net income, showing strong operating leverage (Page 13).
- →2026 revenue guidance range raised by $100 million to $6.3 billion - $6.5 billion (Page 4).
- →GAAP operating income guidance updated to $750 million - $850 million, up from prior guidance (Page 4).
- →Non-GAAP operating income expected to rise correspondingly (Page 4).
- →Earnings per ADS for Q1 were $1.96 GAAP and $3.24 non-GAAP, with strong momentum anticipated (Page 4).
- →Operating expenses growth expected to normalize and align with top-line growth (Page 4).
- →The company anticipates sustained commercial growth across all geographies and pipeline advancement driving value long-term (Page 13).
🏗️ Capital Expenditure Plans
Yes- →The transcript does not explicitly mention current or future capital expenditures (capex) or strategic investments in detail.
- →The company is focused on investing to support commercial growth and rapidly advance its innovative pipeline, as indicated by the 16% increase in operating expenses totaling $1.1 billion.
- →Investments are primarily driving R&D and SG&A growth, expected to normalize over the year.
- →The strategic investment emphasis is on advancing clinical programs, expanding launches (e.g., zanidatamab and Sonro), and strengthening the pipeline through selective external innovation.
- →Examples include acquiring options to license novel assets like the PD-1 VGF CTLA4 trispecific and expanding clinical studies rapidly (e.g., GPC3/4-1BB bispecific in solid tumors).
- →No specific dollar amounts or capital investment plans for physical assets are disclosed in the provided pages.
💰 Fundraising & Capital Structure
No information- →The transcript does not mention any current or planned fundraising activities through debt or equity.
- →Financial discussions focus on revenue growth, operating income, and cash flow generation.
- →The company highlights strong free cash flow ($161 million in Q1) and improved operating income.
- →No references were made to new equity offerings or debt issuances.
- →The company emphasizes efficient R&D investment and sustainable growth without indicating the need for external capital raising at this time.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Frequently Asked Questions
What were BeOne Medicines AG Q2 FY26 results?
- BeOne Medicines projects 2026 revenue between $6.3 billion and $6.5 billion, raising previous guidance by $100 million. - Strong momentum and growth expected in all markets, supported by continued global expansion. - Modest contributions anticipated from launches of zanidatamab and Sonro during 2026. - U.S. - BeOne Medicines is a growth company focused on sustainable growth with continuous operating leverage (Page 13).
What is BeOne Medicines AG share price analysis?
BeOne Medicines AG currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 68.6 with a market cap of $32,305. Investors should review the full earnings analysis for detailed insights.
Is BeOne Medicines AG planning capital expenditure?
- The transcript does not explicitly mention current or future capital expenditures (capex) or strategic investments in detail.
Keep BeOne Medicines AG on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.